Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Primary Purpose
Urinary Incontinence
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vesicare
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Incontinence focused on measuring Incontinence, Robotic Prostatectomy, Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients that have been diagnosed with prostate cancer and will undergo treatment for the disease as part of standard clinical care
- Patients that have multiple pad use a few days after standard of care catheter removal
Exclusion Criteria:
- Contra-indication to Solifenacin
- Narrow angle glaucoma
- Hepatic impairment
- Renal impairment
- CYP3A4 inhibitors (e.g. Ketoconazole)
- Gastric Retention (delayed or slow emptying of the stomach)
- Lives in a different country
Sites / Locations
- University of California, Irvine Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Vesicare
Arm Description
Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
Outcomes
Primary Outcome Measures
Time to Continence
Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.
Secondary Outcome Measures
Full Information
NCT ID
NCT01215721
First Posted
October 5, 2010
Last Updated
December 4, 2013
Sponsor
University of California, Irvine
Collaborators
Astellas Pharma US, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01215721
Brief Title
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Official Title
Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine
Collaborators
Astellas Pharma US, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease. Over 100,000 radical prostatectomies cases (total removal of the cancerous prostate by surgery) are performed in the United States yearly. Unfortunately nearly all of the men undergoing surgery report diminished Quality of Life (QOL) scores due in part due to a postoperative incontinence which may require the use of multiple urinary pads per day. Many of these men also report debilitating irritative voiding symptoms of urinary urgency and frequency, and have overall decreased urinary satisfaction scores. Abatement of these symptoms can take up to one year in men, and in 5-20% of patients symptoms may persist for longer periods.
Our recent published findings suggest that instability in the bladder muscle is likely an underlying etiology in postoperative urinary incontinence. This 'Detrusor Muscle' instability results in excess contractions of the urinary bladder ('urgency to urinate'), and can result in the feeling of needing to urinate more frequently. Consistent with this hypothesis of detrusor muscle instability, men with postoperative dribbling had more complaints with urgency, frequency and bother scores when queried with validated questionnaires. We suspect that a transient bladder muscle contraction may overcome the urinary sphincter valve resistance and result in the patient's dribbling of urine.
By treating the bladder muscle instability, we expect improved postoperative continence and improved quality of life in patients after undergoing surgery for total removal of a cancerous prostate. This pilot study will assess the statistical requirements for the number of subjects needed for a fully 'powered' randomized prospective study to fully evaluate whether medications such as solifenacin significantly improve patients' quality of urinary life and improve postoperative urinary incontinence after surgery.
*This study has been modified from the original protocol with the clinicaltrials.gov ID: NCT00581061.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Incontinence
Keywords
Incontinence, Robotic Prostatectomy, Prostate Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vesicare
Arm Type
Experimental
Arm Description
Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
Intervention Type
Drug
Intervention Name(s)
Vesicare
Other Intervention Name(s)
Vesicare (Solifenacin)
Intervention Description
5 mg daily
Primary Outcome Measure Information:
Title
Time to Continence
Description
Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.
Time Frame
12 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients that have been diagnosed with prostate cancer and will undergo treatment for the disease as part of standard clinical care
Patients that have multiple pad use a few days after standard of care catheter removal
Exclusion Criteria:
Contra-indication to Solifenacin
Narrow angle glaucoma
Hepatic impairment
Renal impairment
CYP3A4 inhibitors (e.g. Ketoconazole)
Gastric Retention (delayed or slow emptying of the stomach)
Lives in a different country
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Ahlering, MD
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
12. IPD Sharing Statement
Links:
URL
http://urology.uci.edu/prostate/
Description
Robotic Prostatectomy | Thomas Ahlering, M.D. | Department of Urology
URL
http://www.urology.uci.edu
Description
Department of Urology | University of California, Irvine
Learn more about this trial
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
We'll reach out to this number within 24 hrs